Bulk Manufacturer of Controlled Substances Application: Continuus Pharmaceutical, 48511 [2022-16989]
Download as PDF
<![CDATA[
48511
Federal Register / Vol. 87, No. 152 / Tuesday, August 9, 2022 / Notices
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Massachusetts 01801, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
Kristi O’Malley,
Assistant Administrator.
The company plans to bulk
manufacture the above listed controlled
substance for research and development
purposes only. No other activities for
these drug codes are authorized for this
registration.
[FR Doc. 2022–16984 Filed 8–8–22; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
9801
II
BILLING CODE P
Bulk Manufacturer of Controlled
Substances Application: Continuus
Pharmaceutical
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
[Docket No. DEA–1056]
Continuus Pharmaceutical
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before October 11, 2022. Such
persons may also file a written request
for a hearing on the application on or
before October 11, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on April 8, 2022,
Continuus Pharmaceutical, 25–R
Olympia Avenue, Woburn,
SUMMARY:
jspears on DSK121TN23PROD with NOTICES
Schedule
[FR Doc. 2022–16989 Filed 8–8–22; 8:45 am]
[Docket No. DEA–1037]
18:04 Aug 08, 2022
Fentanyl ...........................
Drug
code
Kristi O’Malley,
Assistant Administrator.
Drug Enforcement Administration
VerDate Sep<11>2014
Controlled substance
Jkt 256001
Bulk Manufacturer of Controlled
Substances Application:
Biopharmaceutical Research Company
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on June 8, 2022,
Biopharmaceutical Research Company,
11045 Commercial Parkway, Castroville,
California 95012–3209, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
Controlled substance
Marihuana Extract ..............
Marihuana ..........................
Tetrahydrocannabinols ......
Drug
code
7350
7360
7370
Schedule
I
I
I
The company plans to bulk
manufacture the listed controlled
substances to provide Pharmaceuticalgrade marihuana in order to facilitate
research in a manner that complies with
local, state and federal regulations. No
other activities for these drug codes are
authorized for this registration.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–16995 Filed 8–8–22; 8:45 am]
BILLING CODE P
AGENCY:
DEPARTMENT OF JUSTICE
Biopharmaceutical Research
Company has applied to be registered as
a bulk manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before October 11, 2022. Such
persons may also file a written request
for a hearing on the application on or
before October 11, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
SUMMARY:
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
[Docket No. DEA–1059]
Importer of Controlled Substances
Application: Curium US LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Curium US LLC has applied
to be registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before September 8, 2022. Such
persons may also file a written request
for a hearing on the application on or
before September 8, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
DATES:
E:\FR\FM\09AUN1.SGM
09AUN1
]]>Agencies
[Federal Register Volume 87, Number 152 (Tuesday, August 9, 2022)]
[Notices]
[Page 48511]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-16989]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1037]
Bulk Manufacturer of Controlled Substances Application: Continuus
Pharmaceutical
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Continuus Pharmaceutical has applied to be registered as a
bulk manufacturer of basic class(es) of controlled substance(s). Refer
to Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
October 11, 2022. Such persons may also file a written request for a
hearing on the application on or before October 11, 2022.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on April 8, 2022, Continuus Pharmaceutical, 25-R Olympia
Avenue, Woburn, Massachusetts 01801, applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Fentanyl................................ 9801 II
------------------------------------------------------------------------
The company plans to bulk manufacture the above listed controlled
substance for research and development purposes only. No other
activities for these drug codes are authorized for this registration.
Kristi O'Malley,
Assistant Administrator.
[FR Doc. 2022-16989 Filed 8-8-22; 8:45 am]
BILLING CODE P
